492|10000|Public
25|$|The {{category}} of <b>effector</b> <b>T</b> <b>cell</b> {{is a broad}} one that includes various T cell types that actively respond to a stimulus, such as co-stimulation. This includes helper, killer, regulatory, and potentially other T cell types.|$|E
25|$|One major {{difference}} between regulatory T cells and effector T cells is that regulatory T cells typically serve to modulate and deactivate the immune response, while <b>effector</b> <b>T</b> <b>cell</b> groups usually begin with immune-promoting cytokines and then switch to inhibitory cytokines later in their life cycle. The latter is a feature of Th3 cells, which transform into a regulatory subset after its initial activation and cytokine production.|$|E
5000|$|... #Subtitle level 2: Determination of the <b>effector</b> <b>T</b> <b>cell</b> {{response}} ...|$|E
40|$|The {{sensitivity}} of <b>T</b> <b>cells</b> to interleukin- 2 (IL- 2) can vary by three {{orders of magnitude}} and {{is determined by the}} surface densities of the IL- 2 receptor α subunits. Regulatory <b>T</b> <b>cells</b> inflict a double hit on <b>effector</b> <b>T</b> <b>cells</b> by lowering the bulk IL- 2 concentration as well as the {{sensitivity of}} <b>effector</b> <b>T</b> <b>cells</b> to this crucial cytokine. This double hit deprives weakly activated <b>effector</b> <b>T</b> <b>cells</b> of pSTAT 5 survival signals while having only minimal effects on strongly activated effector cells that express increased levels of the IL- 2 receptor. Short-term signaling differences lead to a differential functional in terms of proliferation and <b>cell</b> division: regulatory <b>T</b> <b>cell</b> specifically suppress weakly activated <b>effector</b> <b>T</b> <b>cells</b> even at large numbers; small numbers of strongly activated <b>effector</b> <b>T</b> <b>cells</b> overcome the suppression...|$|R
40|$|Regulatory <b>T</b> <b>cells</b> {{are crucial}} in {{controlling}} various functions of <b>effector</b> <b>T</b> <b>cells</b> during experimental autoimmune encephalomyelitis. While regulatory <b>T</b> <b>cells</b> {{are reported to}} exert their immunomodulatory effects in the peripheral immune organs, their role within {{the central nervous system}} (CNS) during experimental autoimmune encephalomyelitis is unclear. Here, by combining a selectively timed regulatory <b>T</b> <b>cells</b> depletion with 2 -photon microscopy, we report that regulatory <b>T</b> <b>cells</b> exercise their dynamic control over <b>effector</b> <b>T</b> <b>cells</b> in the CNS. Acute depletion of regulatory <b>T</b> <b>cells</b> exacerbated experimental aut oimmune encephalomyelitis sev erity which was accompanied by increased pro-inflammatory cytokine production and prolifer ation of <b>effector</b> <b>T</b> <b>cells.</b> Intravital microscopy revealed that, in the absence of regulatory <b>T</b> <b>cells,</b> the velocity of <b>effector</b> <b>T</b> <b>cells</b> was decreased with simultaneous increase in the proportion of stationary phase cells in the CNS. Based on these data, we conclude that regulatory <b>T</b> <b>cells</b> mediate recovery from experimental autoimmune encephalomyelitis by controlling cytokine production, proliferation and motility of <b>effector</b> <b>T</b> <b>cells</b> in the CNS...|$|R
40|$|Since birth, our {{immune system}} is {{constantly}} bombarded with self-antigens and foreign pathogens. To stay healthy, complex immune strategies have evolved in our immune system to maintain self-tolerance and to defend against foreign pathogens. <b>Effector</b> <b>T</b> <b>cells</b> are the key players in steering the immune responses to execute immune functions. While <b>effector</b> <b>T</b> <b>cells</b> were initially identified to be immune promoting, recent studies unraveled negative regulatory functions of <b>effector</b> <b>T</b> <b>cells</b> in modulating adaptive as well as innate immunity. Owing to their critical and diverse functions in controlling immune responses, the functions and regulation of <b>effector</b> <b>T</b> <b>cells</b> have been a subject of intense investigation. In this review, key information about <b>T</b> <b>cell</b> immunity is summarized. (Turkderm 2013; 47 : Suppl 1 : 18 - 23...|$|R
50|$|Tr1 {{cells can}} express ectoenzymes CD39 and CD73 and are {{suspected}} of generating adenosine which suppresses <b>effector</b> <b>T</b> <b>cell</b> proliferation and their cytokine production in vitro.|$|E
5000|$|Campbell DJ, Kim CH, Butcher EC [...] "Separable <b>effector</b> <b>T</b> <b>cell</b> populations {{specialized}} for B cell help or tissue inflammation." [...] Nat Immunol 2001; 2: 9: 876-81 ...|$|E
5000|$|J.R. Mora, M.R. Bono, N. Manjunath, W. Weninger, M. Rosemblatt, U.H. Von Andrian. [...] "Peyer's patch {{dendritic}} cells provide tissue-specific {{instructions for}} <b>effector</b> <b>T</b> <b>cell</b> homing to the gut". Nature 424:88-93, 2003 ...|$|E
40|$|Background: Nonmyeloablative {{chemotherapy}} {{followed by}} adoptiveimmunotherapy {{is an attractive}} strategy for depleting regulatory <b>T</b> <b>cells</b> in the host. However, its efficacy is transient. Here, we aim to investigate whether cyclic chemoimmunotherapy has therapeutic efficacy against cancer. Methods:We examined the efficacy of cyclic chemoimmunotherapy with cyclophosphamide and adoptively transferred <b>effector</b> <b>T</b> <b>cells</b> against 5 -day, established MCA 205 murine skin sarcomas. Results: Cyclophosphamide administration followed by adoptive immunotherapy augmented the trafficking of <b>effector</b> <b>T</b> <b>cells</b> into established tumors. Further, multiple cyclophosphamide administrations helped <b>effector</b> <b>T</b> <b>cells</b> to persist at the sites. Chemoimmunotherapy achieved complete tumor regression even with the transfer of {{a limited number of}} <b>effector</b> <b>T</b> <b>cells</b> (5 × 106). Conclusion: Cyclic chemoimmunotherapy, which maintains adoptively transferred <b>T</b> <b>cells</b> by impairing regulatory <b>T</b> <b>cells,</b> is a potentially suitable treatment for established tumors...|$|R
40|$|Post {{pathogen}} invasion, {{migration of}} effector T-cell subsets to specific tissue locations is of prime importance for generation of robust immune response. <b>Effector</b> <b>T</b> <b>cells</b> are imprinted with distinct ‘homing codes’ (adhesion molecules and chemokine receptors) during activation which regulate their targeted trafficking to specific tissues. Internal cues in the lymph node microenvironment along with external stimuli from food (vitamin A) and sunlight (vitamin D 3) prime dendritic cells, imprinting {{them to play}} centrestage in the induction of tissue tropism in <b>effector</b> <b>T</b> <b>cells.</b> B cells as well, {{in a manner similar}} to <b>effector</b> <b>T</b> <b>cells,</b> exhibit tissue tropic migration. In this review, we have focused on the factors regulating the generation and migration of <b>effector</b> <b>T</b> <b>cells</b> to various tissues alongwith giving an overview of tissue tropism in B cells...|$|R
40|$|Abstract Background Previously, we {{reported}} that adoptively transferred perforin k/o (PKO), and IFN-γ k/o (GKO), or perforin/IFN-γ double k/o (PKO/GKO) <b>effector</b> <b>T</b> <b>cells</b> mediated regression of B 16 BL 6 -D 5 (D 5) pulmonary metastases {{and showed that}} TNF receptor signaling {{played a critical role}} in mediating tumor regression. In this report we investigated the role of lymphotoxin-α (LT-α) as a potential effector molecules of tumor-specific <b>effector</b> <b>T</b> <b>cells.</b> Methods <b>Effector</b> <b>T</b> <b>cells</b> were generated from tumor vaccine-draining lymph node (TVDLN) of wt, GKO, LT-α deficient (LKO), or PKO/GKO mice and tested for their ability to mediate regression of D 5 pulmonary metastases in the presence or absence of LT-βR-Fc fusion protein or anti-IFN-γ antibody. Chemokine production by D 5 tumor cells was determined by ELISA, RT-PCR and Chemotaxis assays. Results Stimulated <b>effector</b> <b>T</b> <b>cells</b> from wt, GKO, or PKO/GKO mice expressed ligands for LT-β receptor (LT-βR). D 5 tumor cells were found to constitutively express the LT-βR. Administration of LT-βR-Fc fusion protein completely abrogated the therapeutic efficacy of GKO or PKO/GKO but not wt <b>effector</b> <b>T</b> <b>cells</b> (p Conclusion The contribution of LT-α expression by <b>effector</b> <b>T</b> <b>cells</b> to anti-tumor activity in vivo was not discernable when wt <b>effector</b> <b>T</b> <b>cells</b> were studied. However, the contribution of LT-β R signaling was identified for GKO or PKO/GKO <b>effector</b> <b>T</b> <b>cells.</b> Since LT-α does not directly induce killing of D 5 tumor cells in vitro, but does stimulate D 5 tumor cells to secrete chemokines, these data suggest a model where LT-α expression by tumor-specific <b>effector</b> <b>T</b> <b>cells</b> interacts via cross-linking of the LT-βR on tumor cells to induce secretion of chemokines that are chemotactic for macrophages. While the contribution of macrophages to tumor elimination in our system requires additional study, this model provides a possible explanation for the infiltration of inate effector cells that is seen coincident with tumor regression. </p...|$|R
50|$|The {{category}} of <b>effector</b> <b>T</b> <b>cell</b> {{is a broad}} one that includes various T cell types that actively respond to a stimulus, such as co-stimulation. This includes helper, killer, regulatory, and potentially other T cell types.|$|E
5000|$|... #Caption: The time {{course of}} an immune response. Due to the {{formation}} of immunological memory, reinfection at later time points leads to a rapid increase in antibody production and <b>effector</b> <b>T</b> <b>cell</b> activity. These later infections can be mild or even unapparent.|$|E
50|$|CXCR3 is {{expressed}} primarily on activated T lymphocytes and NK cells, and some epithelial cells. CXCR3 and CCR5 are preferentially expressed on Th1 cells, whereas Th2 cells favor {{the expression of}} CCR3 and CCR4. CXCR3 ligands that attract Th1 cells can concomitantly block the migration of Th2 cells in response to CCR3 ligands, thus enhancing the polarization of <b>effector</b> <b>T</b> <b>cell</b> recruitment.|$|E
5000|$|<b>Effector</b> <b>T</b> <b>cells,</b> <b>T</b> <b>cells</b> that {{actively}} {{responds to}} a stimulus ...|$|R
40|$|The neuropeptide alpha-melanocyte {{stimulating}} hormone (α-MSH) has {{an important}} role in modulating immunity and homeostasis. The production of IFN-γ by <b>effector</b> <b>T</b> <b>cells</b> is suppressed by α-MSH, while TGF-β production is promoted in the same <b>cells.</b> Such α-MSH-treated <b>T</b> <b>cells</b> have immune regulatory activity and suppress hypersensitivity, autoimmune diseases, and graft rejection. Previous characterizations of the α-MSH-induced Treg cells showed that the cells are CD 4 + <b>T</b> <b>cells</b> expressing the same levels of CD 25 as <b>effector</b> <b>T</b> <b>cells.</b> Therefore, we further analyzed the α-MSH-induced Treg cells for expression of effector and regulatory T-cell markers. Also, we examined the potential for α-MSH-induced Treg cells to be from the effector T-cell population. We found that the α-MSH-induced Treg cells are CD 25 +[*][*]CD 4 + <b>T</b> <b>cells</b> that share similar surface markers as <b>effector</b> <b>T</b> <b>cells,</b> except that they express on their surface LAP. Also, the α-MSH treatment augments FoxP 3 message in the <b>effector</b> <b>T</b> <b>cells,</b> and α-MSH induction of regulatory activity was limited to the effector CD 25 + T-cell population. Therefore, α-MSH converts <b>effector</b> <b>T</b> <b>cells</b> into Treg cells, which suppress immunity targeting specific antigens and tissues...|$|R
40|$|License, which permits {{unrestricted}} use, distribution, {{and reproduction}} in any medium, provided the original work is properly cited. The neuropeptide alpha-melanocyte stimulating hormone (α-MSH) {{has an important}} role in modulating immunity and homeostasis. The production of IFN-γ by <b>effector</b> <b>T</b> <b>cells</b> is suppressed by α-MSH, while TGF-β production is promoted in the same <b>cells.</b> Such α-MSH-treated <b>T</b> <b>cells</b> have immune regulatory activity and suppress hypersensitivity, autoimmune diseases, and graft rejection. Previous characterizations of the α-MSH-induced Treg cells showed that the cells are CD 4 + <b>T</b> <b>cells</b> expressing the same levels of CD 25 as <b>effector</b> <b>T</b> <b>cells.</b> Therefore, we further analyzed the α-MSH-induced Treg cells for expression of effector and regulatory T-cell markers. Also, we examined the potential for α-MSH-induced Treg cells to be from the effector T-cell population. We found that the α-MSH-induced Treg cells are CD 25 + CD 4 + <b>T</b> <b>cells</b> that share similar surface markers as <b>effector</b> <b>T</b> <b>cells,</b> except that they express on their surface LAP. Also, the α-MSH treatment augments FoxP 3 message in the <b>effector</b> <b>T</b> <b>cells,</b> and α-MSH induction of regulatory activity was limited to the effector CD 25 + T-cell population. Therefore, α-MSH converts <b>effector</b> <b>T</b> <b>cells</b> into Treg cells, which suppress immunity targeting specific antigens and tissues. 1...|$|R
50|$|One major {{difference}} between regulatory T cells and effector T cells is that regulatory T cells typically serve to modulate and deactivate the immune response, while <b>effector</b> <b>T</b> <b>cell</b> groups usually begin with immune-promoting cytokines and then switch to inhibitory cytokines later in their life cycle. The latter is a feature of Th3 cells, which transform into a regulatory subset after its initial activation and cytokine production.|$|E
50|$|In immunology, an {{immunological}} synapse (or immune synapse) is {{the interface}} between an antigen-presenting cell or target cell and a lymphocyte such as an <b>effector</b> <b>T</b> <b>cell</b> or Natural Killer cell. The interface was originally named after neuronal synapse, with which it shares the main structural pattern. Immunological synapse consists of molecules involved in T cell activation, which compose typical patterns - activation clusters. Immunological synapse {{is the subject of}} much ongoing research.|$|E
50|$|Otelixizumab is one {{of several}} investigational {{monoclonal}} antibodies that target CD3, a T lymphocyte receptor involved in normal cell signaling. More specifically, otelixizumab targets the epsilon chain of CD3. Data suggest that the drug works by blocking the function of effector T cells, which mistakenly attack and destroy insulin-producing beta cells, while stimulating regulatory T cells, which are understood to protect against <b>effector</b> <b>T</b> <b>cell</b> damage, thus preserving the beta cells' normal ability to make insulin.|$|E
40|$|The current {{paradigm}} surrounding allergen-mediated T helper type 2 (Th 2) immune {{responses in}} the lung suggests an almost hegemonic role for <b>T</b> <b>cells.</b> Our studies propose an alternative hypothesis implicating eosinophils in the regulation of pulmonary <b>T</b> <b>cell</b> responses. In particular, ovalbumin (OVA) -sensitized/challenged mice devoid of eosinophils (the transgenic line PHIL) have reduced airway levels of Th 2 cytokines relative to the OVA-treated wild type that correlated with a reduced ability to recruit <b>effector</b> <b>T</b> <b>cells</b> to the lung. Adoptive transfer of Th 2 -polarized OVA-specific transgenic <b>T</b> <b>cells</b> (OT-II) alone into OVA-challenged PHIL recipient mice failed to restore Th 2 cytokines, airway histopathologies, and, most importantly, the recruitment of pulmonary <b>effector</b> <b>T</b> <b>cells.</b> In contrast, the combined transfer of OT-II cells and eosinophils into PHIL mice resulted in the accumulation of <b>effector</b> <b>T</b> <b>cells</b> and a concomitant increase in both airway Th 2 immune responses and histopathologies. Moreover, we show that eosinophils elicit {{the expression of the}} Th 2 chemokines thymus- and activation-regulated chemokine/CCL 17 and macrophage-derived chemokine/CCL 22 in the lung after allergen challenge, and blockade of these chemokines inhibited the recruitment of <b>effector</b> <b>T</b> <b>cells.</b> In summary, the data suggest that pulmonary eosinophils are required for the localized recruitment of <b>effector</b> <b>T</b> <b>cells...</b>|$|R
40|$|A {{successful}} <b>T</b> <b>cell</b> {{immune response}} has two major products: <b>effector</b> <b>T</b> <b>cells</b> which {{directly or indirectly}} remove the antigens, and memory <b>T</b> <b>cells,</b> which allow a faster and more efficient recall response when challenged by related antigens. An important issue is whether costimulatory molecules on the antigen-presenting cells are involved in determining whether <b>T</b> <b>cells</b> will differentiate into effector or memory cells after antigenic stimulation. To address this issue, we have produced mice with targeted mutations of either the heat-stable antigen (HSA), or both HSA and CD 28. We show that CD 28 /B 7 and HSA provide two alternative costimulatory pathways for induction of immunological memory to influenza virus. Furthermore, our results revealed that B 7 {{is essential for the}} generation of <b>effector</b> <b>T</b> <b>cells</b> from either naive or memory <b>T</b> <b>cells,</b> while HSA is not necessary for the generation of <b>effector</b> <b>T</b> <b>cells.</b> Our results demonstrate that the induction of memory <b>T</b> <b>cells</b> and <b>effector</b> <b>T</b> <b>cells</b> can utilize distinct costimulatory molecules. These results have important implications on lineage relationship between <b>effector</b> and memory <b>T</b> <b>cells.</b> 1 Abbreviations used in this paper: CTLp, the precursor for cytolytic lymphocytes...|$|R
40|$|Effect of {{treatment}} of mice with cyclophosphamide (CY) on the delayed hypersensitivity (DH) response {{was investigated in}} C 57 BL/ 6 mice. DH to methylated human serum albumin (MHSA) could be enhanced with CY in young mice but not in aged ones. DH enhancement with CY appeared {{to be due to}} elimination of suppressor <b>T</b> <b>cells</b> involved in DH. <b>Effector</b> <b>T</b> <b>cells</b> were also sensitive to CY, the damaging effect of CY on these latter cells was, however, transient suggesting the rapid recovery of <b>effector</b> <b>T</b> <b>cells.</b> The overshooting recovery of the <b>effector</b> <b>T</b> <b>cells</b> required the presence of the thymus. It is more probably that {{there are at least two}} distinct subpopulations of <b>T</b> <b>cells</b> in DH, <b>effector</b> <b>T</b> <b>cells,</b> and suppressor <b>T</b> <b>cells.</b> The distinction is already apparent in the thymus stage. The suppressor <b>T</b> <b>cells,</b> categorized as a central regulator, seem to be antigen nonspecific and regulate the more effectively the DH in young mice, thus physiological role of these cells in age-associated immune alterations is implicated...|$|R
50|$|Targeting immunoregulatory {{membrane}} receptors {{succeeded in}} some patients with melanoma, non-small-cell lung carcinoma, urothelial bladder cancer and renal cell cancer. In mice, anti-CTLA-4 therapy leads to clearance from the tumor of Foxp3+ regulatory T cells (Treg cells) whose presence may impair <b>effector</b> <b>T</b> <b>cell</b> function. Similarly anti-PD-1/anti-PD-L1 therapy blocks the inhibitory PD-1 receptor. Other, potentially more fundamental TME inhibitory reactions (as in microsatellite stable colorectal cancer, ovarian cancer, prostate cancer, and PDA {{have yet to be}} overcome. The TME appears to aid in excluding killer T cells from the vicinity of cancer cells.|$|E
50|$|Improved {{antitumor}} responses {{have been}} seen in mouse and monkey models using T cells in early differentiation stages (such as naïve or central memory cells). CD8+ T cells follow a progressive pathway of differentiation from naïve T cells into stem cell memory, central memory, effector memory, and ultimately terminally differentiated <b>effector</b> <b>T</b> <b>cell</b> populations. CD8+ T cells paradoxically lose antitumor power as they acquire the ability to lyse target cells and to produce the cytokine interferon-γ, qualities otherwise thought to be important for antitumor efficacy. Differentiation state is inversely related to proliferation and persistence. Age is negatively correlated with clinical effectiveness. CD8+ T cells can exist in a stem cell-like state, capable of clonal proliferation. Human T memory stem cells express a gene program {{that enables them to}} proliferate extensively and differentiate into other T cell populations.|$|E
40|$|Since the {{discovery}} of T helper type 1 and type 2 <b>effector</b> <b>T</b> <b>cell</b> subsets 20 years ago, inducible regulatory T cells and interleukin 17 (IL- 17) -producing T helper cells {{have been added to}} the 'portfolio' of helper T cells. It is unclear how many more <b>effector</b> <b>T</b> <b>cell</b> subsets there may be and to what degree their characteristics are fixed or flexible. Here we show that transforming growth factor-beta, a cytokine at the center of the differentiation of IL- 17 -producing T helper cells and inducible regulatory T cells, 'reprograms' T helper type 2 cells to lose their characteristic profile and switch to IL- 9 secretion or, in combination with IL- 4, drives the differentiation of 'T-H- 9 ' cells directly. Thus, transforming growth factor-beta constitutes a regulatory 'switch' that in combination with other cytokines can 'reprogram' <b>effector</b> <b>T</b> <b>cell</b> differentiation along different pathways...|$|E
5000|$|... #Caption: Diagram of {{regulatory}} <b>T</b> <b>cell,</b> <b>effector</b> <b>T</b> <b>cells</b> and dendritic cell showing putative mechanisms of suppression by regulatory <b>T</b> <b>cells.</b>|$|R
5000|$|Regulatory <b>T</b> <b>cells</b> {{can produce}} Granzyme B, {{which in turn}} can induce {{apoptosis}} of <b>effector</b> <b>cells.</b> Regulatory <b>T</b> <b>cells</b> from Granzyme B deficient mice are reported to be less effective suppressors of the activation of <b>effector</b> <b>T</b> <b>cells.</b>|$|R
40|$|Latent HIV type I (HIV- 1) infections can {{frequently}} {{occur in}} short-lived proliferating <b>effector</b> <b>T</b> lymphocytes. These latently infected cells could revert into resting T lymphocytes and thereby {{contribute to the}} establishment of the long-lived viral reservoir. Monocyte-derived dendritic cells can revert latency in <b>effector</b> <b>T</b> <b>cells</b> in vitro. Here we investigated the latency activation properties of tissue-specific immune cells, including a large panel of dendritic cell subsets, to explore in which body compartments <b>effector</b> <b>T</b> <b>cells</b> are most likely to maintain latent HIV- 1 provirus and thus potentially contribute to the long-lived reservoir. Our results demonstrate that blood or genital tract dendritic cells do not activate latent provirus in <b>effector</b> <b>T</b> <b>cells,</b> whereas gut or lymphoid dendritic cells induce virus production from latently infected <b>effector</b> <b>T</b> <b>cells</b> in our in-vitro model for latency. Toll-like receptor 3 -induced interferon production by myeloid dendritic cells abolished the dendritic cells' ability to induce viral gene expression. In this study, we show that HIV- 1 provirus residing in <b>effector</b> <b>T</b> <b>cells</b> is activated from latency by tissue-specific dendritic cell subsets and other immune cells with remarkably different efficiencies. Our new assay system points to an important, neglected aspect of HIV- 1 research: the ability of other immune cells, especially dendritic cells, to differentially affect latency establishment as well as virus reactivatio...|$|R
40|$|The {{salivary glands}} {{represent}} a major site of cytomegalovirus replication and transmission to other hosts. Despite control of viral infection by strong T cell responses in visceral organs cytomegalovirus replication {{continues in the}} salivary glands of mice, suggesting that the virus exploits the mucosal microenvironment. Here, we show that T cell immunity in the salivary glands {{is limited by the}} induction of CD 4 T cells expressing the regulatory cytokine interleukin (IL) - 10. Blockade of IL- 10 receptor (IL- 10 R) with an antagonist antibody dramatically reduced viral load in the salivary glands, but not in the spleen. The mucosa-specific protection afforded by IL- 10 R blockade was associated with an increased accumulation of CD 4 T cells expressing interferon [gamma], suggesting that IL- 10 R signaling limits <b>effector</b> <b>T</b> <b>cell</b> differentiation. Consistent with this, an agonist antibody targeting the tumor necrosis factor receptor superfamily member OX 40 (TNFRSF 4) enhanced <b>effector</b> <b>T</b> <b>cell</b> differentiation and increased the number of interferon [gamma]–producing T cells, thus limiting virus replication in the salivary glands. Collectively, the results indicate that modulating <b>effector</b> <b>T</b> <b>cell</b> differentiation can counteract pathogen exploitation of the mucosa, thus limiting persistent virus replication and transmission...|$|E
40|$|Background/aims: <b>Effector</b> <b>T</b> <b>cell</b> {{activation}} {{is particularly}} important in the initiation of autoimmune uveitis. This pilot study seeks to demonstrate activation of human peripheral effector T cells {{in response to the}} uveitis candidate autoantigen, retinal S antigen (SAg), using cytokine flow cytometry (CFC) ...|$|E
40|$|Interleukin- 2 (IL- 2) signals {{influence}} various lymphocyte subsets during differentiation, immune {{responses and}} homeostasis. As {{discussed in this}} Review, stimulation with IL- 2 is crucial {{for the maintenance of}} regulatory T (T(Reg)) cells and for the differentiation of CD 4 (+) T cells into defined <b>effector</b> <b>T</b> <b>cell</b> subsets following antigen-mediated activation. For CD 8 (+) T cells, IL- 2 signals optimize both <b>effector</b> <b>T</b> <b>cell</b> generation and differentiation into memory cells. IL- 2 is presented in soluble form or bound to dendritic cells and the extracellular matrix. Use of IL- 2 - either alone or in complex with particular neutralizing IL- 2 -specific antibodies - can amplify CD 8 (+) T cell responses or induce the expansion of the T(Reg) cell population, thus favouring either immune stimulation or suppression...|$|E
40|$|The adoptive {{transfer}} of <b>effector</b> <b>T</b> <b>cells</b> combined with lymphodepletion has demonstrated promising antitumor effects in mice and humans, although {{the availability of}} tumor-specific <b>T</b> <b>cells</b> is limited. We and others have also demonstrated that the transfer of polyclonal naïve <b>T</b> <b>cells</b> induces tumor-specific <b>effector</b> <b>T</b> <b>cells</b> and enhances antitumor immunity after lymphodepletion. Because tumors have been demonstrated to induce immunosuppressive networks and regulate the function of <b>T</b> <b>cells,</b> obtaining {{a sufficient number of}} fully functional naïve <b>T</b> <b>cells</b> that are able to differentiate into tumor-specific <b>effector</b> <b>T</b> <b>cells</b> remains difficult. To establish culture methods to obtain a large number of polyclonal <b>T</b> <b>cells</b> that are capable of differentiating into tumor-specific <b>effector</b> <b>T</b> <b>cells,</b> naïve <b>T</b> <b>cells</b> were activated with anti-CD 3 mAbs in vitro. These cells were stimulated with IL- 2 and IL- 7 for the CD 8 subset or with IL- 7 and IL- 23 for the CD 4 subset. Transfer of these hyperexpanded <b>T</b> <b>cells</b> after lymphodepletion showed significant antitumor efficacy, and tumor-specific <b>effector</b> <b>T</b> <b>cells</b> were primed from these expanded <b>T</b> <b>cells</b> in tumor-bearing hosts. Moreover, these ex vivo-expanded <b>T</b> <b>cells</b> maintained <b>T</b> <b>cell</b> receptor diversity and showed long-term persistence of memory against specific tumors. Further analyses revealed that combination therapy consisting of vaccination with dendritic cells that were co-cultured with irradiated whole tumor cells and the transfer of ex vivo-expanded <b>T</b> <b>cells</b> significantly enhanced antitumor immunity. These results indicate that the transfer of ex vivo-expanded polyclonal <b>T</b> <b>cells</b> can be combined with other immunotherapies and augment antitumor effects...|$|R
5000|$|Enhanced {{grafting}} of adoptively transferred, tumor-reactive <b>effector</b> <b>T</b> <b>cells</b> by {{the creation}} of an immunologic space niche.|$|R
30|$|The TLR 9 agonist CpG {{has been}} shown to {{eradicate}} murine intracranial glioma when subcutaneously administered with tumor lysate and <b>effector</b> <b>T</b> <b>cells</b> (Wu et al., 2007). Further investigation into local administration of CpG analyzed the change in the balance between <b>effector</b> <b>T</b> <b>cells</b> and regulatory <b>T</b> <b>cells</b> at the tumor site. The ratio of CD 8 + <b>T</b> <b>effector</b> <b>cells</b> to CD 4 +FoxP 3 + Tregs in the tumor environment was shown to be increased. In CLNs, antigen-specific activation of CD 4 + and CD 8 + <b>T</b> <b>cells</b> was observed with CpG administration (Grauer et al., 2007).|$|R
